Objectives: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, affecting about 5% of the population over 60 years old. This condition is associated with an increased risk of arterial thromboembolism and stroke particularly ischemic stroke. Anticoagulant therapy can substantially reduce these complications. The aim of this analysis is to estimate the non pharmacological costs and consequences of the use of apixaban compared with warfarin in the treatment of patients with non-valvular atrial fibrillation (NVAF) in Colombia. MethOds: An excel model was adapted to simulate the cost and outcomes based on a hypothetic cohort of 1,000,000 patients annually. The comparators were: apixaban (5 mg BID) with warfarin (INR 2.0 to 3.0). The prevalence of AF data was taken from a local study .The effectiveness and safety data were taken from ARISTOTLE study (n= 18,201). The analysis used the third payer perspective including only direct medical costs. The costs of medical procedures were taken from the ISS tariffs and expressed in 2013 $ US (1 $ US= 1.934 COP). The results were measured in terms of number of events of stroke/systemic embolism, major bleedings and deaths presented annually. Results: The results were as follows: events of stroke/systemic embolism apixaban 73 and warfarina 93; major bleedings apixaban 123 and warfarina 179; and deaths apixaban 203 and warfarina 228. The Model results indicate that apixaban compared to enoxaparin would prevent per year: 20 stroke/systemic embolism events, 56 major bleedings and 25 deaths. Apixaban compared with warfarin would save annually on average $ US 184,227 for the cohort of simulated patients, distributed as follows: $ US 85,938 (47 %) in care of stroke/systemic embolism and $ US 98,262 (53 %) in care of major bleedings. cOnclusiOns: In this analysis, apixaban demonstrates better expected health outcomes with lower expected associated costs, in the Colombian health system. Objectives: Thrombolysis has not been fully implemented into clinical practice in the developing world primarily due to economic restraints. The study assessed the cost-effectiveness (CE) and estimated annual savings of thrombolysis with recombinant tissue plasminogen activator (rt-PA, alteplase) within 4.5 hours after acute ischemic stroke (AIS) versus standard care from the Mexican Institute of Social Security (IMSS) perspective. Standard care (SC) was defined as inpatient treatment of the AIS without utilization of thrombolytic agents. MethOds: A decision-analytic model was developed. Efficacy, direct costs and resources were obtained from IMSS available data and published studies. Effectiveness outcomes included the percentage of patients who responded favorably to treatment (no disability and able to carry out all usual activities) between the time of diagnosis + 1 year (time horizon). Additionally analyses evaluated cost savings in patients with AIS (> 80 years old) who responded favorably to the treatment. Discount rates were not applied to the model. A sensitivity analysis was conducted to evaluate the impact of the uncertainty variables. Results: The estimated total cost per patient was $23,53.20 for SC and $23,663.93 for rt-PA. The percentage of patients who responded favorably to treatment was 16% in the rt-PA and 12% in SC. The CER were USD $193,241.02 for SC and USD$146,924.34 for rt-PA. This equated to a cost-savings of $46,316.67/ percentage of patients recovered with no symptoms/disabilities. The projected savings over a five-year period (2013)(2014)(2015)(2016)(2017) in the IMSS ranged from $9,626,458 and $22,015,454. cOnclusiOns: The results from the analyses indicated that rt-PA provided a highly cost-effective and saving alternative compared with SC. In medical settings where thrombolysis is not yet a common practice, rt-PA is a cost effective treatment to improve functional outcome in patients treated promptly after acute ischemic stroke. Salud, S.A. de C.V., Mexico City, Mexico, 3 Market Access and Government Sales Department, Naucalpan, Mexico, 4 Hospital General de México O.D., Mexico City, Mexico Objectives: To analyse the incremental cost-effectiveness ratio (ICER) between combination angiotensin II receptor antagonists + thiazides. Specifically, comparing azilsartan + clortalidona vs. current available treatments: valsartan + hydrochlorothiazide, telmisartan + hydrochlorothiazide, losartan + hydrochlorothiazide and irbesartan + hydrochlorothiazide. MethOds: Cost-effectiveness analysis was conducted using a Markov model with a 35-year temporal horizon for patients over the age of 45 and diagnosed with systemic arterial hypertension. The model adopts the Mexican public health institutions' perspective. Four health states were incorporated: healthy, hypertensive with non-fatal acute myocardial infarction (AMI), hypertensive with non-fatal stroke and death. Transition probabilities were calculated based on the national risk of stroke or AMI, and the probability of having a vascular complication depending on blood pressure levels (in mmHg). Costs and effectiveness data were taken from public health institutions, producer pharmaceutical companies or extracted from published literature. Final outcome was measured in ICER per life year gained (LYG). Cost-effectiveness was determined according to the 1GDP/capita threshold established by the National Health Council in Mexico. Results: Azilsartan + chlortalidone was found to be dominant compared to all other treatments with a total cost of USD$2,873.57 over 35 years, and an effectiveness of 12.23 LYG. The next most cost-effective comparator, losartan + hydrochlorothiazide, presented an ICER of USD$349.21; however due to a difference in efficacy of -0.68 LYG, azilsartan + chlortalidone remained dominant even with a 10% increase in price. cOnclusiOns: Azilsartan + chlortalidone was found to be dominant in comparison with all other included treatments. Azilsartan is therefore a very cost-effective intervention for the Mexican population over 45 with systemic arterial hypertension.
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ValidaTioN of The aPixabaN CosT-effeCTiVeNess model iN PaTieNTs WiTh NoN-ValVular aTrial fibrillaTioN
Kachroo S. 1 , Phatak H. 1 , Dorian P. 2 , Kongnakorn T. 3 , Lanitis T. 4 , Kuznik A. 5 , Mardekian J. 6 , Liu X. 7 , Lawrence J. 8 , Lip G. Y. 9 1 Princeton, NJ, USA, 2 University of Toronto, Toronto, ON, Canada, 3 Evidera, Bangkok, Thailand, 4 Evidera, London, UK, 5 Celgene Corporation, Summit, NJ, USA, 6 Pfizer, New York, NY, USA, 7 Pfizer, Inc. & University of Tennessee College of Pharmacy, New York, NY, USA, Princeton, NJ, USA, 9 University of Birmingham, Birmingham, UK Objectives: The purpose of this study was to assess the predictive validity of an apixaban cost-effectiveness model by comparing key event rates from the model to those seen in the ARISTOTLE trial where apixaban was compared with vitamin K antagonist (VKA) in patients with non-valvular atrial fibrillation (NVAF). MethOds: A Markov model was developed to assess the cost effectiveness of apixaban versus comparators including VKA. The model was set to the settings of the ARISTOTLE and the key event rates were compared by setting time horizon same as ARISTOTLE. Predictive validity of the model was checked by comparing key outcomes to the source data. Results: Overall, the model closely predicted event-based hazard ratio (HR) for warfarin versus apixaban for various end-points including ischemic and unspecified stroke (HR: 1.09 vs 1.08 for trial vs. model). Similar results were observed for intracranial hemorrhages (HR: 2.38 vs. 2.25), other major bleeds (HR: 1.27 vs. 1.24) and myocardial infarction (HR: 1.14 vs. 1.13). Importantly, death was accurately predicted by this model with HR of 1.13 vs. 1.12 seen in the trial. Slight variations in the HR may be attributable to the sequential structure of the model where event rates associated with aspirin therapy after warfarin discontinuation were derived from AVERROES patients on aspirin who were previously treated with warfarin (@42%). Other major bleeds and clinically relevant non-major bleeds rates were slightly different, as these events were modeled as transient states to mimic real life treatment patterns. cOnclusiOns: The model appears to predict event rates seen in ARISTOTLE trial, thus demonstrating the model's ability to accurately replicate the trial results within the trial period. This study demonstrates the applicability of this model to estimate cost-effectiveness of new interventions in similar populations.
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CosT effeCTiVeNess of drug eluTiNg ballooN Versus PerCuTaNeous TraNslumiNal ballooN aNgioPlasTy, bare meTal sTeNT aNd drug eluTiNg sTeNT iN The TreaTmeNT of PeriPheral arTerial disease iN loWer limbs Colombia
